

Paula Iruzubieta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2143797/paula-iruzubieta-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42
papers

513
citations

14
h-index

21
g-index

48
ext. papers

811
ext. citations

5.8
avg, IF

3.66
L-index

#	Paper	IF	Citations
42	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.. <i>Hepatology</i> , 2022 ,	11.2	2
41	Can NAFLD overwhelm the Spanish healthcare system in the years to come?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 114, 5-9	0.9	
40	Biochemical assessment of metabolic associated fatty liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021 , 2, 199-208	1.3	1
39	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. <i>Cancer Research</i> , 2021 , 81, 2874-2887	10.1	10
38	Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFN̄and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. <i>Viruses</i> , 2021 , 13,	6.2	1
37	Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. <i>Scientific Reports</i> , 2021 , 11, 9819	4.9	1
36	Bilirrubina: Medicin̄ y utilidad cl̄nica en la enfermedad hep̄tica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021 , 2, 362-372	1.3	
35	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , 2021 , 9, 892-902	5.3	3
34	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. <i>JHEP Reports</i> , 2021 , 3, 100276	10.3	0
33	Let̄s leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. <i>Journal of Hepatology</i> , 2021 , 75, 224-226	13.4	0
32	SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. <i>Journal of Hepatology</i> , 2021 , 74, 966-967	13.4	7
31	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 1627-1633 ⁸	16.4	8
30	Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. <i>Journal of Hepatology</i> , 2021 , 74, 469-471	13.4	23
29	Valoracīn bioqūmica en la enfermedad hep̄tica grasa asociada a la disfuncīn metab̄lica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021 , 2, 209-219	1.3	
28	National digestive disease specialists survey on cardiovascular risk management in non-alcoholic fatty liver disease in spanish hospitals. <i>Liver International</i> , 2021 , 41, 1243-1253	7.9	0
27	Measurement and clinical usefulness of bilirubin in liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021 , 2, 352-361	1.3	1
26	Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH. <i>Journal of Hepatology</i> , 2021 , 75, 34-45	13.4	4

25	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
24	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. <i>Molecular Metabolism</i> , 2021 , 53, 101275	8.8	2
23	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.. <i>Biomedicines</i> , 2021 , 10,	4.8	2
22	A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
21	Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. <i>Nature Communications</i> , 2020 , 11, 3360	17.4	34
20	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. <i>Cell Metabolism</i> , 2020 , 31, 605-622.e10	24.6	24
19	LOXL2-A New Target in Antifibrogenic Therapy?. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	31
18	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. <i>Digestive and Liver Disease</i> , 2019 , 51, 95-103	3.3	8
17	Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
16	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2019 , 29, 40-54	8.8	17
15	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. <i>Cells</i> , 2019 , 8,	7.9	7
14	Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. <i>World Journal of Clinical Cases</i> , 2018 , 6, 611-623	1.6	2
13	Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 3655-3667	6.9	15
12	Metabolic effects of reduced growth hormone action in fatty liver disease. <i>Hepatology International</i> , 2018 , 12, 474-481	8.8	14
11	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease 2018 ,		3
10	Hepatic p63 regulates steatosis via IKK β /ER stress. <i>Nature Communications</i> , 2017 , 8, 15111	17.4	32
9	Resistance to hepatitis C virus. Implications and therapeutic options. <i>Gastroenterology & Hepatology</i> , 2017 , 40, 484-494	0.9	1
8	Deregulated neddylation in liver fibrosis. <i>Hepatology</i> , 2017 , 65, 694-709	11.2	28

7	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. <i>Nature Communications</i> , 2017 , 8, 2068	17.4	45
6	A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , 2017 , 12, e0173914	3.7	18
5	Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	17
4	The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?. <i>BioMed Research International</i> , 2015 , 2015, 386186	3	15
3	Plasma betatrophin levels in patients with liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10662-8	5.6	12
2	Vitamin D deficiency in chronic liver disease. <i>World Journal of Hepatology</i> , 2014 , 6, 901-15	3.4	63
1	Long-term survival after liver transplantation for alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2013 , 19, 9198-208	5.6	42